Tecfidera and Fatigue and fatigability in RRMS
- Conditions
- Fatigue, Fatigability, relapsing-remitting multiple sclerosis, force, dimethyl fumarate
- Registration Number
- NL-OMON25337
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•Informed consent
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
•History of alcohol or drug abuse or current alcohol or drug abuse
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Description of the association between measures of fatigability and fatigue in pwRRMS after 16 weeks of treatment with dimethyl fumarate (Tecfidera).
- Secondary Outcome Measures
Name Time Method 1) Description of the effect of 16-week treatment with DMF on fatigue as quantified with the Fatigue severity scale (FSS) in pwRRMS. 2) Description of the effect of 16-week treatment with DMF on fatigability as quantified by a decline in muscle force and changes in voluntary drive in relapsing-remitting MS patients.